18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study-Reference-Cited by-同舟云学术

18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study

Published:2013-05-21 Issue:6 Volume:28 Page:1337-1347
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Frost Michelle L¹,Moore Amelia E¹,Siddique Musib¹,Blake Glen M¹,Laurent Didier²,Borah Babul²,Schramm Ursula²,Valentin Marie-Anne²,Pellas Theodore C²,Marsden Paul K³,Schleyer Paul J³,Fogelman Ignac¹

Affiliation:

1. Osteoporosis Screening and Research Unit; King's College London; King's Health Partners; Guy's Campus; London; United Kingdom

2. Novartis Pharma AG; Basel; Switzerland

3. PET Imaging Centre; King's College London; King's Health Partners; St Thomas' Campus; London; United Kingdom

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.1862/fullpdf

Reference47 articles.

1. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective;Bouxsein;J Bone Miner Res.,2008